Zolpidem Prescribing Guidelines

Introduction to Zolpidem Use

Zolpidem can be appropriately prescribed on an as-needed (PRN) basis for insomnia, with moderate-strength evidence supporting this approach, though scheduled dosing remains more commonly studied, as recommended by the American Academy of Sleep Medicine 1, 2

The FDA has established sex-specific dosing recommendations due to slower drug clearance in women, with recommended doses of 5 mg immediate-release (IR) or 6.25 mg extended-release (ER) for women and 5-10 mg IR or 6.25-12.5 mg ER for men, as supported by the American Academy of Sleep Medicine 3, 4
These lower doses were mandated in 2013 after discovery that higher morning blood levels caused next-day driving impairment, particularly in women, highlighting the importance of dosing guidelines from the American Academy of Sleep Medicine 5

PRN zolpidem is supported by clinical trial evidence and represents a valid prescribing strategy, with three RCTs (n=607) demonstrating that zolpidem 10 mg as-needed reduced sleep onset latency by 15 minutes and increased total sleep time by 48 minutes on nights when taken, as reported by the American Academy of Sleep Medicine 1, 2
One trial showed 54% of patients reported "much or very much improved" global outcomes versus 24% with placebo, indicating the effectiveness of PRN zolpidem as recommended by the American Academy of Sleep Medicine 1, 2

The American Academy of Sleep Medicine provides a weak recommendation for zolpidem in treating both sleep onset and maintenance insomnia, emphasizing it should supplement—not replace—cognitive behavioral therapy for insomnia (CBT-I), as supported by the American Academy of Sleep Medicine 3, 4, 6

Zolpidem carries significant safety risks that must be weighed against benefits, including common adverse effects such as amnesia, dizziness, somnolence, nausea, drowsiness, and altered taste, as reported by the American Academy of Sleep Medicine 4, 6
Serious safety concerns include complex sleep behaviors, such as sleep-driving and hallucinations, as well as increased risk of falls and fractures, and suicide risk, highlighting the need for caution when prescribing zolpidem as recommended by the American Academy of Sleep Medicine 1, 2, 6

Despite FDA warnings, approximately 50% of women Veterans continued receiving high-dose prescriptions (>5 mg) after the 2013 dosing change, indicating widespread non-adherence to guidelines from the American Academy of Sleep Medicine 5
Common prescribing errors include prescribing 10 mg to women (should be 5 mg maximum) and failing to reduce dose in elderly patients, as cautioned by the American Academy of Sleep Medicine 5

When discontinuing zolpidem, taper slowly to avoid withdrawal seizures and rebound insomnia rather than stopping abruptly, as recommended by the American Academy of Sleep Medicine 6

Zolpidem demonstrates clinically significant improvement in sleep onset latency (11-19 minutes reduction) and is comparable in efficacy to benzodiazepines but with potentially fewer next-day cognitive effects when dosed appropriately, as reported by the American College of Physicians 6
The American College of Physicians recommends cognitive behavioral therapy for insomnia as first-line treatment before pharmacologic options, making zolpidem most appropriate as an adjunct rather than standalone therapy, as supported by the American Academy of Sleep Medicine 6